Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gyre Therapeutics (GYRE) Total Debt: 2009-2015

Historic Total Debt for Gyre Therapeutics (GYRE) over the last 6 years, with Dec 2015 value amounting to $1.2 million.

  • Gyre Therapeutics' Total Debt fell 95.86% to $28,000 in Q3 2016 from the same period last year, while for Sep 2016 it was $28,000, marking a year-over-year decrease of 95.86%. This contributed to the annual value of $1.2 million for FY2015, which is N/A change from last year.
  • Per Gyre Therapeutics' latest filing, its Total Debt stood at $1.2 million for FY2015, which was up 1.76% from $1.1 million recorded in FY2013.
  • Gyre Therapeutics' 5-year Total Debt high stood at $3.2 million for FY2011, and its period low was $1.1 million during FY2013.
  • Moreover, its 2-year median value for Total Debt was $1.1 million (2013), whereas its average is $1.1 million.
  • In the last 5 years, Gyre Therapeutics' Total Debt grew by 5.49% in 2011 and then tumbled by 42.83% in 2013.
  • Over the past 4 years, Gyre Therapeutics' Total Debt (Yearly) stood at $3.2 million in 2011, then plummeted by 38.43% to $2.0 million in 2012, then plummeted by 42.83% to $1.1 million in 2013, then reached $1.2 million in 2015.